Data on: Cell Signaling and Targeted Drug Therapy of Cancer

The landmark Cancer Genomics Program launched in 2006 has contributed immensely to the awareness of the importance of cancer genomics in our understanding of cancer over the past decade and has begun to change the way the disease is treated in clinic. A large number of mutations contribute to cancer and predicting the effects of mutations using in silico tools has become a frequently used approach, but the use of next-generation sequencing-based approaches in clinical diagnosis has also led to a considerable increase in data and a vast number of variants of uncertain significance that require further analysis and validation to achieve the development goals. These data cannot be analyzed simply by using the tools and techniques traditionally available to better understand the origin and evolution of cancer and therefore to achieve this goal, a cancer reference framework through modeling of genome sequencing data has been proposed for the systematic identification of representative driver networks to predict cancer progression and associated clinical phenotypes. It is based on the consideration that possible observable combinations of these mutations must converge on a few common signaling pathways and networks responsible for tumor growth and cancer progression. In this way, it aims to analyze data to explain how different genetic mutations in different patients have the same downstream effects on the protein machinery, ultimately leading to the analysis of the characteristic pathway of cancer progression. The Cancer Genome Atlas (TCGA) Program is the landmark cancer genomics program initiated by the NIH, and has contributed immensely to realizing the importance of genomics in cancer research. The synchronized vision of oncogenic processes based on PanCancer Atlas analyzes attempts to elucidate the possible consequences of genome alterations on the different signaling pathways involved in human cancers, also reflecting on their influence on the tumor microenvironment and immune cells, to provide new information about development of new forms of targeted drugs and immunotherapies. Considering the genes and pathways affecting different cancer types and individual tumors vary considerably, a complete understanding of these alterations becomes essential to identify vulnerabilities and discover precise therapeutic solutions. A comprehensive analysis of tumors based on their genomic studies must reveal the alterations in signaling pathways indicating patterns of vulnerabilities and the means to identify prospective targets for the development of personalized treatments and new combination therapies. The TCGA Research Network has profiled and analyzed a large number of human tumors to discover molecular aberrations at the DNA, RNA, protein, and epigenetic levels and thereby provided reliable diagnostic and prognostic biomarkers for different cancer types since then. Further, the Cancer Cell Map Initiative (CCMI), launched in 2015 by researchers at the University of California, San Francisco and the University of California, San Diego, allowed researchers to determine how hundreds of genetic mutations involved in a few types of cancer affect the activity of certain crucial proteins which ultimately lead to the manifestation of cancer. As there is a large amount of sequence data from many different cancer types, efforts are being made to extract mechanistic insights from the available information, requiring an integrated computational and experimental strategy that will help place these alterations in the higher order contexts of signaling mechanisms in cancer cells. This is the defined goal of the CCMI and has the potential to create a resource that can be used for cancer genome interpretation, enabling the identification of key complexes and pathways to be studied more mechanistically to better understand the biology underlying different cancer types and conditions. Additionally, the Cancer Dependency Map (DepMap) initiative at the Broad Institute of MIT and Harvard, an academic-industry partnership program officially announced in 2019, is devoted to cancer research aimed at accelerating precision cancer medicine by creating a comprehensive map of tumor vulnerabilities and identifying key cancer biomarkers. This program focuses on screening thousands of cancer cell lines using RNA interference (RNAi) and CRISPR-Cas9 gene editing strategies to identify genes whose expression may be affected and found to be essential for cell transformation. CRISPR-Cas9 gene editing is an efficient method of modifying the genome of almost any cell type. CRISPR editing and screening have emerged as powerful tools for studying nearly all aspects of cellular behaviors which have greatly influenced our understanding of cancer biology and continue to contribute to new discoveries. A related project called Cancer Cell Line Encyclopedia (CCLE), started as a collaboration between the Broad Institute and the Novartis Institute for Biomedical Research in 2008, appears well suited for large-scale genetic characterization of thousands of cancer cell lines in order to link characteristics genetic alterations with distinct pharmacological vulnerabilities, and to translate integrative genomics into patients stratification for personalized cancer treatments. By accessing critical genomic data via CCLE, such as gene mutations, chromosome copy number, gene expression and methylation profiles, scientists can now predict new synthetic lethality and identify new molecular markers for selectively targeting cells with specific genetic changes. Thus, the initiative provides a rigorous foundation on which to study genetic variants and candidate targets, identify new marker-based cancer diagnostics, and design anticancer agents for critical cancers therapies. The challenge of identifying relevant genes and signaling molecules for different types of cancer using cutting-edge technologies will remain an essential part of cancer research and precision oncology and will most likely help vulnerable individuals receive effective treatment for cancer. The related article aims to fully determine the landscape of precision oncology research and seek solutions based on these initiatives in cancer research.